Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial (NCT04400838), 54 HIV positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) receiv...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society for Clinical Investigation
2022
|
| _version_ | 1797106624822771712 |
|---|---|
| author | Ogbe, A Pace, M Bittaye, M Tipoe, T Adele, S Alagaratnam, J Aley, PK Ansari, MA Bara, A Broadhead, S Brown, A Brown, H Cappuccini, F Cinardo, P Dejnirattisai, W Ewer, K Fok, H Folegatti, PM Fowler, J Godfrey, L Goodman, AL Jackson, B Jenkin, D Jones, M Longet, S Makinson, RA Marchevsky, NG Mathew, M Mazzella, A Mujadidi, YF Parolini, L Petersen, C Plested, E Pollock, K Rajeswaran, T Ramasamy, MN Rhead, S Robinson, H Robinson, N Sanders, H Serrano Fandos, S Tipton, T Waters, A Zacharopoulou, P Barnes, E Dunachie, S Goulder, P Klenerman, P Screaton, GR Winston, A Gilbert, SC Pollard, AJ Lambe, T Frater, J |
| author_facet | Ogbe, A Pace, M Bittaye, M Tipoe, T Adele, S Alagaratnam, J Aley, PK Ansari, MA Bara, A Broadhead, S Brown, A Brown, H Cappuccini, F Cinardo, P Dejnirattisai, W Ewer, K Fok, H Folegatti, PM Fowler, J Godfrey, L Goodman, AL Jackson, B Jenkin, D Jones, M Longet, S Makinson, RA Marchevsky, NG Mathew, M Mazzella, A Mujadidi, YF Parolini, L Petersen, C Plested, E Pollock, K Rajeswaran, T Ramasamy, MN Rhead, S Robinson, H Robinson, N Sanders, H Serrano Fandos, S Tipton, T Waters, A Zacharopoulou, P Barnes, E Dunachie, S Goulder, P Klenerman, P Screaton, GR Winston, A Gilbert, SC Pollard, AJ Lambe, T Frater, J |
| author_sort | Ogbe, A |
| collection | OXFORD |
| description | Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial (NCT04400838), 54 HIV positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and MesoScale Discovery (MSD)), neutralisation, ACE-2 inhibition, gamma interferon ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that 6 months after vaccination the majority of measurable immune responses were greater than pre-vaccination baseline, but with evidence of a decline in both humoral and cell mediated immunity. There was, however, no significant difference compared to a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although were lower than wild type. Pre-existing cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater post-vaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the on-going policy to vaccinate PWH against SARS-CoV-2, and underpin the need for long-term monitoring of responses after vaccination. |
| first_indexed | 2024-03-07T07:05:09Z |
| format | Journal article |
| id | oxford-uuid:b2656203-370d-4fe5-b84e-aef6fa2fb2c0 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:05:09Z |
| publishDate | 2022 |
| publisher | American Society for Clinical Investigation |
| record_format | dspace |
| spelling | oxford-uuid:b2656203-370d-4fe5-b84e-aef6fa2fb2c02022-04-20T14:26:53ZDurability of ChAdOx1 nCov-19 vaccination in people living with HIVJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b2656203-370d-4fe5-b84e-aef6fa2fb2c0EnglishSymplectic ElementsAmerican Society for Clinical Investigation2022Ogbe, APace, MBittaye, MTipoe, TAdele, SAlagaratnam, JAley, PKAnsari, MABara, ABroadhead, SBrown, ABrown, HCappuccini, FCinardo, PDejnirattisai, WEwer, KFok, HFolegatti, PMFowler, JGodfrey, LGoodman, ALJackson, BJenkin, DJones, MLonget, SMakinson, RAMarchevsky, NGMathew, MMazzella, AMujadidi, YFParolini, LPetersen, CPlested, EPollock, KRajeswaran, TRamasamy, MNRhead, SRobinson, HRobinson, NSanders, HSerrano Fandos, STipton, TWaters, AZacharopoulou, PBarnes, EDunachie, SGoulder, PKlenerman, PScreaton, GRWinston, AGilbert, SCPollard, AJLambe, TFrater, JDuration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial (NCT04400838), 54 HIV positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and MesoScale Discovery (MSD)), neutralisation, ACE-2 inhibition, gamma interferon ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that 6 months after vaccination the majority of measurable immune responses were greater than pre-vaccination baseline, but with evidence of a decline in both humoral and cell mediated immunity. There was, however, no significant difference compared to a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although were lower than wild type. Pre-existing cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater post-vaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the on-going policy to vaccinate PWH against SARS-CoV-2, and underpin the need for long-term monitoring of responses after vaccination. |
| spellingShingle | Ogbe, A Pace, M Bittaye, M Tipoe, T Adele, S Alagaratnam, J Aley, PK Ansari, MA Bara, A Broadhead, S Brown, A Brown, H Cappuccini, F Cinardo, P Dejnirattisai, W Ewer, K Fok, H Folegatti, PM Fowler, J Godfrey, L Goodman, AL Jackson, B Jenkin, D Jones, M Longet, S Makinson, RA Marchevsky, NG Mathew, M Mazzella, A Mujadidi, YF Parolini, L Petersen, C Plested, E Pollock, K Rajeswaran, T Ramasamy, MN Rhead, S Robinson, H Robinson, N Sanders, H Serrano Fandos, S Tipton, T Waters, A Zacharopoulou, P Barnes, E Dunachie, S Goulder, P Klenerman, P Screaton, GR Winston, A Gilbert, SC Pollard, AJ Lambe, T Frater, J Durability of ChAdOx1 nCov-19 vaccination in people living with HIV |
| title | Durability of ChAdOx1 nCov-19 vaccination in people living with HIV |
| title_full | Durability of ChAdOx1 nCov-19 vaccination in people living with HIV |
| title_fullStr | Durability of ChAdOx1 nCov-19 vaccination in people living with HIV |
| title_full_unstemmed | Durability of ChAdOx1 nCov-19 vaccination in people living with HIV |
| title_short | Durability of ChAdOx1 nCov-19 vaccination in people living with HIV |
| title_sort | durability of chadox1 ncov 19 vaccination in people living with hiv |
| work_keys_str_mv | AT ogbea durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT pacem durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT bittayem durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT tipoet durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT adeles durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT alagaratnamj durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT aleypk durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT ansarima durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT baraa durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT broadheads durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT browna durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT brownh durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT cappuccinif durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT cinardop durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT dejnirattisaiw durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT ewerk durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT fokh durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT folegattipm durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT fowlerj durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT godfreyl durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT goodmanal durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT jacksonb durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT jenkind durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT jonesm durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT longets durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT makinsonra durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT marchevskyng durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT mathewm durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT mazzellaa durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT mujadidiyf durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT parolinil durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT petersenc durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT plestede durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT pollockk durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT rajeswarant durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT ramasamymn durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT rheads durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT robinsonh durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT robinsonn durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT sandersh durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT serranofandoss durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT tiptont durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT watersa durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT zacharopouloup durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT barnese durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT dunachies durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT goulderp durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT klenermanp durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT screatongr durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT winstona durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT gilbertsc durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT pollardaj durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT lambet durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv AT fraterj durabilityofchadox1ncov19vaccinationinpeoplelivingwithhiv |